Diagnostic Radiopharmaceuticals And Contrast Media Market is Estimated To Witness High Growth Owing To Digitalization in Medical Imaging
The diagnostic radiopharmaceuticals and contrast media market is estimated to be valued at US$ 6,811.4 Mn in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Diagnostic radiopharmaceuticals and contrast media are medical imaging agents used for non-invasive diagnosis and therapeutic purposes. Radiopharmaceuticals are radiolabelled molecules that facilitate medical imaging techniques such as PET and SPECT scans, while contrast media agents help enhance vascular and organ visualization during diagnostic procedures such as CT scans, X-rays, MRIs and ultrasound. They provide valuable information about organ function, blood flow and abnormalities in the human body.
Market key trends:
Digitalization is increasingly influencing medical imaging technology through advancements such as artificial intelligence, cloud computing, and enhanced visualization. AI technologies have enabled more precise diagnoses by processing and analyzing large diagnostic imaging data. Cloud connectivity facilitates easy access to images from remote locations. Enhanced visualization using 4D and higher resolution images allows better detection of abnormalities. These digital trends are driving higher demand for advanced radiotracers and contrast agents required for high resolution diagnostic imaging procedures. For instance, radiopharmaceutical tracer 18F-fludeoxyglucose (18F-FDG) is gaining popularity in PET imaging scans due to its increased capability of detecting malignant tumors through AI image analysis.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate due to high capital requirement for R&D, manufacturing, distribution, and stringent regulatory norms. Bargaining power of buyers: The bargaining power of buyers is moderate as they have choice from various diagnostic radiopharmaceuticals and contrast media available in the market. Bargaining power of suppliers: The bargaining power of suppliers is low due to presence of many suppliers and raw material providers. Threat of new substitutes: The threat of new substitutes is low as diagnostic radiopharmaceuticals and contrast media have limited substitutes. Competitive rivalry: The competitive rivalry is high among existing players.
SWOT Analysis
Strength: Diagnostic radiopharmaceuticals and contrast media have wide acceptance in medical imaging techniques. They enable early diagnosis of various diseases. Weakness: Strict regulatory approvals and handling of radioactive materials add to production costs. Short shelf life of some radiopharmaceuticals is also a concern. Opportunity: Increasing prevalence of chronic diseases and growing geriatric population present significant growth opportunities. Rising healthcare expenditure in developing nations boosts market growth. Threats: Side effects associated with use of contrast agents and radiotracers can hamper market revenues. stringent regulations delay new product approvals.
Key Takeaways
The global Diagnostic Radiopharmaceuticals And Contrast Media Market Share is expected to witness high growth, exhibiting CAGR of 5.8% over the forecast period, due to increasing prevalence of chronic diseases such as cancer cardiovascular diseases. North America dominates the global market and is estimated to maintain its dominance over the forecast period owing to availability of advanced healthcare facilities and presence of major players in the region. Europe is the second largest market globally and is expected to exhibit lucrative growth opportunities owing to increasing healthcare expenditure and government support for research activities.
Asia Pacific is anticipated to show fastest growth over the coming years led by rising healthcare expenditure, increasing penetration of medical insurance, growing awareness about diagnostic imaging and infrastructure development in emerging economies like India and China.
Key players operating in the diagnostic radiopharmaceuticals and contrast media market are Siemens Healthineers, Nordion Inc., Lantheus Holdings Inc., Guerbet Group, GE Healthcare, Curium, Bracco Imaging SpA, Bayer AG, Cardinal Health Inc., and NTP Radioisotopes SOC Ltd. Major players are focused on new product approvals, acquisitions and geographical expansion strategies to gain competitive edge in the market.
Read More,